Skip to content Skip to footer
Spotlight Interview_Cary Claiborne

CXO Talks: Cary Claiborne from Adial Pharmaceuticals in a Stimulating Dialogue Exchange with PharmaShots

Welcome to the sixth episode of CXO Talks, featuring Cary Claiborne, CEO of Adial Pharmaceuticals a clinical-stage biopharmaceutical company dedicated to developing therapies for the treatment and prevention of addiction and related disorders. Taking a walk down memory lane, Cary shares the inspiration behind founding Adial Pharmaceuticals. He recounts how an early study at the…

Read more

Viewpoints_Mark Gurney

PharmaShots Interview: Tetra Therapeutics’ Mark Gurney Shares Insight on Topline Results of BPN14770 for Fragile X Syndrome

In an interview with PharmaShots, Mark Gurney, CEO at Tetra Therapeutics shared his views on the results of the P-II exploratory study of BPN14770 in adult patients with Fragile X Syndrome.Shots:The P-II study is a two-way crossover study assessing BPN14770 (25mg, bid) vs PBO in 30 adult male patients aged 18-45yrs. with FXS due to >200 CGG…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]